Hemp Synergistics is a biotechnology company with the goal to make a meaningful difference in the hemp industry. We work to accomplish this goal through scientific innovation and operational excellence.
A Quick IntroductionLearn About Bio-DriLearn About CannaBOOSTWe stand behind
Science. Quality. Solutions.
Solutions for
-
Food and Beverage
-
Nutraceutical
-
Cosmetics
-
Law Enforcement
Click links to find out more
-
CannaBoost™ CBD capsule with Enhanced Enzymatic Delivery
-
Bio-Dri™ Patent-Pending Broad Spectrum Powder
-
TRU: THC Recognition Unit™ for Law Enforcement
Concentration is Key
Bio-Dri™ Powder with Enhanced Enzymatic Delivery
Bio-Dri™ is a patent pending novel broad-spectrum hemp powder concentrations up to 55% and Cannabidiol (CBD) up to 50%.
Keep the powder off of the production room floor
- Formable Powder
- Projected 99% capsule fill yield
- Easy & consistent capsule slug formation
Bio-Dri™ uses 5x less space than the competition.
Solutions for
Manufacturers
Cannabinoids pair nicely with everything from anti-inflammatories to zinc. Formulators are now empowered to include therapeutic doses of more active ingredients producing better results and repeat customers!
Investment Protection
Bio-Dri™ uses long chain glucose polymers fully encapsulating each hemp oil droplet protecting the customer’s investment from destructive stomach acids delivering a 100% intact molecule ready for absorption in the small intestines.
Dilution is Bad
Most other CBD powders have a maximum CBD concentration of 10%. This low concentration leaves little room for supporting ingredients. Our patent pending manufacturing process not only delivers superior absorption capabilities, but also freedom to flex your formulating muscles.
Combining CannaBoost™ with cannabinoids (including CBD) will significantly reduce absorption loss due to first pass metabolism thereby significantly increasing oral bioavailability.(7,8)*
Flexibility is Good
Bio-Dri™ comes in CBD concentrations ranging from 18% to 50% to fit any encapsulation project. Our free-flowing product will pair well with the most troublesome hydroscopic ingredients further opening endless formulating possibilities.
We don’t sell you products – we provide science and peace of mind.
With over 50 years of regulatory, DOH, DEP, and controlled substance testing and laboratory management, Hemp Synergistics knows more about quality control and producing to large-scale than any other provider in the hemp industry. If you want the peace of mind that comes from knowing exactly what is in the product your business depends on, partner with Hemp Synergistics to supply your CBD and other cannabinoids.
Our StoryLearn About CannaBOOSTFirst Pass Metabolism Solutions
CBD Capsule with Enhanced Enzymatic Delivery
Our new CBD Capsule addresses the primary problem with all ingested cannabinoids: Sub-Standard Bioavailability.
First Pass
Metabolism Solutions
The first pass effect (also known as first-pass metabolism) is a phenomenon of drug potency loss whereby the concentration of a drug or nutraceutical, specifically when administered orally, is greatly reduced before it reaches the circulatory system.
Cannabinoid Bioavailability
The oral bioavailability of all cannabinoids is very low (0.3-19%)1 primarily due to massive loss caused by the P450 enzyme superfamily. Most of the loss is caused by the prominent CYP3A4 enzyme.2,3
CannaBoost™
CANNABOOST™ temporarily renders these enzymes inactive by utilizing the inhibition properties of various nutraceuticals.* Specifically, curcumin(5), naringin (6,7) and BioPerine® (4,5) have demonstrated CYP3A4 inhibition abilities.
Combining CANNABOOST™ with cannabinoids (including CBD) will significantly reduce absorption loss due to first pass metabolism thereby significantly increasing oral bioavailability.(7,8)*
Bio-Dri™ Protects CBD*
Patent pending Bio-Dri™ encapsulates and protects cannabinoids from stomach acids and enzymes delivering an ‘intact’ molecule ready for absorption.* Bio-Dri™ works hand in hand with CANNABOOST™ maximizing every milligram of CBD and other minor cannabinoids.*
1. Milar S, Stone N, Yates A, O’Sullivan S. A systematic review of the pharmacokinetics of cannabidiol in humans. Frontiers in Pharma 26 Nov 2018
2. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences 89 (2011) 165-170
3. Zendulka O, Dovrelova G, Noskova K, Turjap M, Sulcova A, Hanus L, Jurica J. Cannabinoids and Cytochrome P450 Interactions. Curr Drug Metab 2016;17(3):206-26
4. Rajinder K. Bhardwaj, Hartmut Glaeser, Laurent Becquemont, Ulrich Klotz, Suresh K. Gupta and Martin F. Fromm. Piperine. A Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. August 2002, 302 (2) 645-650
5. Volak L, Ghirmai S, Cashman J, and Court M. Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008 Aug; 36(8): 1594–1605.
6. Ho P C, Saville D J, Coville P F, Wanwimolruk S. Content of CYP3A4 Inhibitors, Naringin, Naringenin and Bergapten in Grapefruit and Grapefruit Juice Products. Pharm Acta Helv. 2000 Apr;74(4):379-85.
7. Fasinu P, Choonara Y, Khan R, Du Toit L C, Kumar P, Ndesendo V, Pillay V. Flavonoids and Polymer Derivatives as CYP3A4 Inhibitors for Improved Oral Drug Bioavailability. J Pharm Sci . 2013 Feb;102(2):541-55.
8. Wadhwa S, Singhal S, Rawat S. Bioavailability Enhancement by Piperine: A Review. Asian J Biomed & Pharm Sciences. Vol 4, Issue 36, 2014.
*These statements have not been evaluated by the FDA. This product is not intended to treat, diagnose, or cure any disease. Consult your personal medical professional before use.
